A blood test tied to Alzheimer's disease could help flag who is more likely to develop dementia years before memory problems become obvious. The test looks for p-tau217, a protein marker associated with the disease process, and may offer a simpler way to estimate future cognitive risk in older adults.
According to the report, symptom-free adults with very high levels of p-tau217 had a 78% likelihood of cognitive decline within 10 years. The findings suggest the test may help identify elevated risk in a five- to 10-year window, potentially long before noticeable symptoms appear.
Researchers are increasingly focused on blood-based tools because they may be less invasive and easier to use than other forms of Alzheimer's screening. A test like this could eventually support earlier monitoring, risk assessment and planning for patients and families if further validated.
While the results point to promising progress, a predictive blood test is not the same as a diagnosis. More research will likely be needed to confirm how accurately p-tau217 levels forecast dementia across broader groups of adults and how the test could fit into routine care.
